Spain Polyphenols Applications is postponed to 2021

Dear Colleagues,

 

In response to the critical situation and evolution of the COVID-19, the Organizing Committee of Polyphenols Applications 2020 decided to postpone the congress to next year.

 

We will announce the details as soon as the planning of the 2021 meeting has been completed.

 

We will keep your registration, you don’t need to do anything.  In case of cancellation, the Organizing Committee will fully refund you.
Thank you for your understanding of this exceptional situation.

 

We will keep our optimism and wish rapidly to overcome these moments.

 

All our warm regards,

 

Prof. Dr. Andreas Schieber                      
President of Polyphenols Applications 2020
University of Bonn, Germany 

 

Natural polyphenols in preclinical models of epilepsy

Natural polyphenols are being tested both in preclinical and clinical settings for the treatment of different neurological disorders. The article describes the outcome of three polyphenols, resveratrol, epigallocatechin gallate, and quercetin, in preclinical animal models of epilepsy (both acute and chronic) and epileptogenesis. In theory, the antioxidant and neuroprotective properties of these natural polyphenols might be valuable in the management of acute seizures and the prevention of epileptogenesis. It is fascinating to observe that these polyphenols have a capacity to alter various signaling processes involved in the pathogenesis of epilepsy. The antiepileptic or antiseizure potential with these molecules delivers a mixed outcome. Some studies have demonstrated the usefulness of these molecules in preclinical models of epilepsy; however, contrary to the findings also exist. These molecules have poor bioavailability that may remain as the limiting factor in their clinical effects. The use of nanotechnology and other techniques have been tested to enhance bioavailability and brain penetration. There are no randomized double-blinded clinical studies establishing their antiepileptic effects in humans. It is concluded that more preclinical mechanism-based studies are needed to deliver a more certain picture regarding the use of natural polyphenols in the treatment of epilepsy.

Author: Ashish Dhir